This is followed by variable degrees of SM dissection and completion of circumferential mucosal incision. Finally a snare assisted resection is performed either en bloc or piecemeal, depending on the polyp size and extent of SM dissection.

**Results**

127 polyps in 127 patients of mean age 71 years. Mean polyp size 46 mm (20–170 mm), 27% were >50 mm. 27% were scarred from past attempted resection. 26% were in the right colon.

En bloc resection: 58/127(46%). Size ≤50 mm was a significant predictor of en bloc resection (88 vs. 12%).

The complication rate was 25/127(19.6%) with 4(3.1%) diathermy damage to muscle fibres and 1 (0.7%) perforation. Complications were not linked to polyp size, scarring or resection site. A single patient with perforation required surgery. All other complications were managed endoscopically.

The recurrence rate was 14/106(13%). This was significantly higher for polyps >50 mm (p = 0.009) and in scarred polyps (p = 0.042).

On sub-analysis of unscared polyps, polyps ≤50 mm with no scarring had a very low recurrence rate of 3.2% as compared to 25% in polyps >50 mm (p = 0.005).

Factors associated with recurrence

**Conclusion**

This is the largest reported western series demonstrating the feasibility, safety and efficacy of KAR for large and refractory polyps, with or without scarring, at all colonic sites. Our data demonstrates that complications of KAR are not related to size but the recurrence rate is. Size >50 mm and scarring seem to be predictors of recurrence.

We propose flat polyps 20–50 mm in size as the ideal indication for KAR in the western setting.

**Disclosure of Interest** None Declared.

---

**Abstract OC-013 Table 1**

<table>
<thead>
<tr>
<th>Size</th>
<th>Resection type</th>
<th>Site</th>
<th>Scarred</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤50 mm</td>
<td>&gt;50 mm</td>
<td>En bloc</td>
<td>P meal</td>
</tr>
<tr>
<td>All polyp recurrence 14/106 (13%)</td>
<td>6/78 (7.6%)</td>
<td>8/28 (28.5%)</td>
<td>1/42 (2.3%)</td>
</tr>
<tr>
<td>P = 0.009</td>
<td>P = 0.001</td>
<td>P = 0.15</td>
<td>P = 0.024</td>
</tr>
<tr>
<td>Unscared polyp recurrence 8/86 (9.3%)</td>
<td>2/62 (3.2%)</td>
<td>6/24 (25%)</td>
<td>1/42 (2.3%)</td>
</tr>
<tr>
<td>P = 0.005</td>
<td>P = 0.018</td>
<td>P = 0.195</td>
<td></td>
</tr>
</tbody>
</table>

---

**OC-014**

**PATIENTS WITH INTRAMUCOSAL CARCINOMA ARISING IN BARRETT’S ESOPHAGUS HAVE SIMILAR OUTCOMES TO THOSE WITH HIGH GRADE DYSPLASIA: DATA FROM THE UNITED KINGDOM REGISTRY**

1,2RJ Haidry*, 1M Banks, 1A Gupta, 2M Butt, 2G Fullarton, 3H Smart, 1J Morris, 3R Willett, 4R Narayanasamy, 1M Rodriguez-Justo, 4M Novelli, 2,3L Lovat. 1UC, London, UK; 2UCL, London, UK; 3NMLC, UCL, London, UK; 2GRI, Glasgow, UK; 4RLUH, Liverpool, UK; 3MRI, Manchester, UK; 5St James Hospital, Dublin, Ireland

10.1136/gutjnl-2014-307263.14

**Introduction**

Mucosal neoplasia arising in Barrett’s oesophagus (BE) can be treated with combined radiofrequency ablation (RFA) and endoscopic mucosal resection (EMR). Once there is submucosal invasion the risk of lymph node metastases increases and surgery is favoured. High grade dysplasia (HGD) and intramucosal carcinoma (IMC) arising from the mucosal layer in BE are defined as separate entities in the revised Vienna classification (category 4.1 and 4.4 respectively).

**Methods**

We examine prospective data from United Kingdom (UK) registry of patients undergoing RFA/EMR for BE neoplasia over past 5 years to compare outcomes between HGD and IMC patient cohorts. Histological confirmation of HGD or IMC was required on two separate occasions by specialist histopathologists prior to treatment. Before RFA, visible lesions were removed by EMR. Thereafter patients underwent RFA 3 monthly following which biopsies were taken at 12 months for clearance of dysplasia (CR-D) and BE (CR-IM). Twelve month outcomes, frequency of EMR, cancer progression and long term durability in both groups were examined.

**Results**

To date 367 patients with HGD and 125 with IMC have been treated. There is no difference in age, sex, baseline BE length between the 2 groups. EMR prior to RFA is far more prevalent in IMC cohort than HGD patients (78 vs. 45%, P < 0.0001). Patients had an average of 2–3 RFA treatments over 12 months (range 1–6) in both cohorts. Rescue EMR after starting RFA for new lesions was similar in both groups (HGD 7%, IMC 6.5%). CR-D and CR-IM in the HGD cohort was 85 and 69% respectively at 12 months. This was not significantly different in the IMC cohort (86 and 71%, p = 0.7). Overall progression to invasive cancer was not significantly different in either cohort (HGD 4.1%, IMC 7.2%). Kaplan Meir survival statistics did not show any difference in long term durability of successful neoplasia treatment in both groups (p = 0.9, log rank test), median follow-up 20 months.

**Conclusion**

We report one of the largest series of patients undergoing endoscopic therapy for IMC arising in BE. Patients with IMC are more likely to have visible lesions that require EMR prior to RFA than those with HGD. However, once all visible lesions are removed, there is no statistical difference in clinical outcomes between the cohorts. Minimally invasive endoscopic therapy with RFA/EMR is a safe and effective treatment in patients with IMC. All collaborators of the UK RFA registry are acknowledged for their contributions to this work.

**Disclosure of Interest** None Declared.

---

**OC-015**

**HIGH GRADE DYSPLASIA ARISING IN BARRETT’S ESOPHAGUS CAN BE ACCURATELY DIAGNOSED COMBINING FOURIER TRANSFORM INFRARED SPECTROSCOPY AND SINGLE ELEMENT ATTENUATED TOTAL REFLECTANCE FTIR DATA**

1L Foreman, 2RJ Haidry*, 3M Banks, 2M Novelli, 4M Rodriguez-Justo, 1D Dougan, 5Szazar, 1P Rich, 2L Lovat. 1UC, London, UK; 2UCL, London, UK; 3MRI, Manchester, UK; 5Imperial College, London, UK

10.1136/gutjnl-2014-307263.15

**Introduction**

Fourier transform infrared spectroscopy (FTIR) detects specific molecules in human tissue from unique vibrational absorption spectra in the mid Infra-Red region (1800–
900 cm⁻¹). Single element Attenuated total reflectance (ATR) contains averaged FTIR spectra from the superficial 10 microns of an entire oesophageal biopsy. We aim to extract individual cellular characteristics with molecular resolution by using FTIR and ATR on ex-vivo oesophageal biopsy specimens from patients undergoing endoscopy for BE surveillance or neoplasia assessment to detect high grade dysplasia (HGD).

**Methods** 731 spectra of 374 fresh biopsies from 76 patients were analysed. Biopsies were taken from visible BE. Before being placed in formalin, they were analysed by a spectrometer fitted with liquid nitrogen-cooled detector and ATR silicon prism. For each spectrum 500 interferograms were averaged before Fourier transformation. Spectra were pre-processed using MATLAB scripts by spectrally removing liquid water and water vapour contributions, vector normalising to the 1610–900 cm⁻¹ region and second derivative conversion to remove baseline artefacts. Specific cellular characteristics were first determined. Unstained 8 μm tissue sections from 1 patient were analysed with FPA (Focal Plane Array)-FTIR imaging and correlated with stained slides. It was possible to accurately describe specific features of squamous epithelium (SQ), columnar lined epithelium (CLE), and lamina propria (LP) with this method. These features were applied to the 374 fresh biopsies using ATR-FTIR. Combined clustering and partial least squares regression discriminants of squamous epithelium (SQ), columnar lined epithelium (CLE), and lamina propria (LP) with this method. These features were applied to the 374 fresh biopsies using ATR-FTIR. Combined clustering and partial least squares regression discrimination (PLSDA) was used to build a diagnostic pipeline. Biopsies were grouped according to their cellular characteristics from the prior FTIR imaging. (1. SQ vs Rest, 2. SQ only biopsies, 3. CLE only biopsies, 4. CLE and LP containing biopsies and 5. LP containing biopsies only).

**Results** We distinguished SQ mucosa from CLE (BE), HGD and OAC tissue at an overall sensitivity of 89% and specificity of 91%. By grouping the spectra into groups according to their cellular contents, HGD was distinguished from all other biopsies with sensitivities and specificities of 68 and 89% (CLE only), 74 and 82% (CLE and LP) and 94 and 97% (LP only) respectively.

**Conclusion** Combined FTIR and ATR-FTIR spectroscopy can accurately distinguish HGD arising in BE on ex-vivo biopsy specimens and might become accurate enough to exclude routine histopathological evaluation in these patients.

**Disclosure of Interest** None Declared.

---

**OC-016 THE TOLL-LIKE RECEPTOR PATHWAY IS RECURRENTLY MUTATED IN OESOPHAGEAL ADENOCARCINOMA**

1Drs Fels Elliott, 1CS Ross-Irnes, 2MD Eldridge, 3RF Fitzgerald on behalf of OCCAMS oesophageal International Cancer Genome Consortium. 1Hutchison/MRC Cancer Unit, University of Cambridge, Cambridge, UK; 2Oxford University Hospital NHS Trust, Oxford, UK; 3Histopathology, Cambridge University Hospital NHS Trust, Cambridge, UK

10.1136/gutjnl-2014-307263.16

**Introduction** The interaction between the oesophageal microbiota and the inflammatory microenvironment in Barrett’s carcinogenesis is poorly understood. One of the mechanisms by which microbiota may induce chronic inflammation is by triggering Toll-like receptor (TLR) signalling and activation of nuclear factor kappa B. We aimed to utilise whole genome sequencing (WGS) data to investigate TLR mutations and expression in oesophageal adenocarcinoma (OAC), with a focus on TLR9.

**Methods** We interrogated the mutational profiles of 66 OAC samples, with matched germline references from each case, which had undergone WGS as part of the oesophageal ICGC study. All mutations were verified using PCR and Sanger sequencing. To further explore TLR9 expression along the Barrett’s progression sequence, we performed TLR9 immunohistochemistry on tissue microarray samples including normal squamous oesophagus (N=16), duodenum (N=14), non-dysplastic Barrett’s (N=53), low-grade dysplasia (N=13), high-grade dysplasia (N=25) and OAC (N=338). Within the large cohort of OAC samples we binarised the intensity scores (0–1 and 2–3) and examined whether there were any significant differences in relation to clinicopathologic variables (TNM stage, histological grade, lymphovascular invasion, survival).

**Results** We identified missense mutations in TLR pathway genes in 8/66 (12.1%) of OAC samples, including TLR1 (1.5%), TLR4 (3%), TLR7 (1.5%), TLR9 (3%), MYD88 (1.5%), and TRAF6 (1.5%). TLR9 protein was expressed more highly in Barrett’s and OAC than normal oesophageal squamous tissue (p < 0.001). The expression in Barrett’s was similar to duodenum, however immunopositivity was increased in OAC (p < 0.05) compared with this control tissue. The staining intensity was generally consistent throughout the Barrett’s progression sequence with strong immunopositivity (intensity score 3) in 7.7–14.5% of samples. Within the OAC cohort, there was no significant association between TLR9 expression and any of the clinicopathological variables tested. The only significant difference in survival was observed in a small subset of patients with metastatic disease (N = 14 patients), where median survival was significantly decreased for patients with TLR9 intensity score 2–3 (8 months ± 2.24 (standard error)) compared to patients with TLR9 intensity score 0–1 (18 months ± 6.57), p < 0.05.

**Conclusion** TLR pathway genes appear to be recurrently mutated in OAC, which given the mutational context and heterogeneity of disease could represent significant involvement of the TLR signalling pathway in Barrett’s carcinogenesis.

**REFERENCE**


**Disclosure of Interest** None Declared.

---

**OC-017 AUTOFLUORESCENCE-TARGETED OPTICAL BIOPSY ACCURATELY DIAGNOSES DYSPLASIA IN BARRETT’S OESOPHAGUS AND CAN DETECT THE FIELD OF MOLECULAR CHANGE**

1MD Di Pietro, 2E Bird-Lieberman, 1X Liu, 3MO Medical Research Council, Cambridge, UK; 2Oxford University Hospital NHS Trust, Oxford, UK; 3Histopathology, Cambridge University Hospital NHS Trust, Cambridge, UK

10.1136/gutjnl-2014-307263.17

**Introduction** Probe-based confocal laser endomicroscopy (pCLE) allows optical biopsies in Barrett’s oesophagus (BO) to predict histological outcome but it is subject to sampling error if performed in a random fashion. We used autofluorescence imaging (AFI) to direct pCLE and added molecular biomarkers to the histopathological diagnosis. The aims of this study were to assess the diagnostic accuracy for dysplasia of AFI-targeted optical biopsies and to investigate the correlation between pCLE patterns and field of molecular change.

**Methods** 46 patients with BO (non-dysplastic BE n = 20, indefinite for dysplasia n = 4, low grade dysplasia n = 10, high grade dysplasia (HGD) or intramucosal cancer (IMC) n = 12) were recruited at a single centre. Patients underwent high-resolution endoscopy followed by AFI and then pCLE was performed on AFI positive (AFI+) areas. Targeted biopsies were taken from